Boston Therapeutics (BTHE) 0.1399 $BTHE
Boston Therapeutics' Hong Kong Affiliate Advance Pharmaceutical's BTI-320 Clinical Trial Reaches Mid-Point by Enrolling 30 Patients at the Chinese University of Hong Kong
Marketwired - Wed Jul 08, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), is conducting a clinical trial at The Chinese University of Hong Kong (CUHK) to evaluate BTI-320 in subjects who are pre-diabetic. The clinical trial has enrolled 30 of the planned 60 patients. Also, the interim analysis in the proof of concept trial is due to be reported shortly.
Boston Therapeutics Presents Findings of BTI-320, a Novel, Non-Systemic, Non-Hypoglycemic Drug Candidate as Therapy to Manage Blood Glucose at 75th Annual Meeting of the American Diabetes Association
Marketwired - Mon Jun 08, 5:19AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will present data on BTI-320, its novel, non-systemic, non-hypoglycemic drug candidate to manage blood glucose, as a poster presentation at the 75th Annual Meeting of the American Diabetes Association being held in Boston, June 5th to the 9th.
EC clears Boehringer Ingelheim's Synjardy
Seeking Alpha - at Seeking Alpha - Thu May 28, 9:22AM CDT
ABT: 49.93 (+0.74), TNDM: 11.47 (+0.28), VTAE: 10.26 (-0.25), LLY: 88.29 (+0.81), ALR: 52.77 (+0.40), MNKD: 5.38 (+0.25), HPTX: 45.99 (+0.02), JNJ: 99.53 (+1.13), NVO: 57.68 (+2.91), MRK: 57.95 (+0.57), SNY: 51.49 (+2.71), VKTX: 6.95 (-0.10)
Boston Therapeutics & University at Buffalo's Translational Pharmacology Research Core Initiates BTI-320 Clinical Trials Alliance in Buffalo, NY and NYC's Chinatown
Marketwired - Thu May 28, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) signed a Letter of Intent with Dr. Gene D. Morse, Director of the Translational Pharmacology Research Core in the University at Buffalo's Center of Excellence for Bioinformatics and Life Sciences (CBLS) to potentially collaborate on an enrollment program for a preventative clinical trials initiative at several locations in Buffalo, NY and New York City's Chinatown. The purpose of this collaboration initiative is to evaluate the effects of BTI-320 on an individual's HbA1c levels, in particular, who are diabetic and pre-diabetic. HbA1c test provides an overall measurement of blood sugar levels over two to three months.
Boston Therapeutics, Inc. Reports First Quarter Results and Provides Corporate Update
Marketwired - Wed May 20, 3:55PM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate chemistry, today reported its financial results for the first quarter and three months ended March 31, 2015 and provided a corporate update.
Boston Therapeutics Announces Fourth Quarter and Fiscal Year 2014 Financial Results and Provides Corporate Update
Marketwired - Fri Mar 27, 12:15PM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate chemistry, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2014 and provided a corporate update.
Boston Therapeutics' Affiliate Advanced Pharmaceutical Initiates SUGARDOWN(R) Clinical Trial in Hong Kong
Marketwired - Wed Mar 25, 5:37AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), affiliate in Hong Kong, Advance Pharmaceutical Company, Ltd. (APC), initiated enrollment of the first subjects in a clinical trial at The Chinese University of Hong Kong to evaluate the effects of SUGARDOWN(R) who are pre-diabetic. (Trial posted on ClinicalTrials.gov)
Boston Therapeutics and Advance Pharmaceutical Expand sugardown(R) Licensing Agreement to Japan; Increases Number of Asian Countries to 16
Marketwired - Tue Mar 17, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of complex carbohydrates to treat diabetes and inflammatory diseases, and Advance Pharmaceutical Company Ltd. (APC), via its subsidiary Sugardown Company Ltd.(SDCL) of Hong Kong, have agreed to expand their licensing and marketing agreement for Boston Therapeutics' sugardown(R) to include Japan. The territory expansion comes as a result of the continued regulatory filings and marketing clearance authorizations that are being granted as APC continues its market registration expansion.
WSA Medical Spotlight
Marketwired - Tue Feb 17, 1:00PM CST
Hansen Medical, Inc.'s (NASDAQ: HNSN) CEO Cary Vance discussed the company's robotic systems and catheters as well as their recent IVC filter retrieval breakthrough. Mr. Vance stated he believes Hansen's technology addresses many key trends and issues hospitals are facing today including revenue-generation and cost containment. He talked about some of the benefits the IVC filter provides patients such as much safer and more effective procedures. Mr. Vance outlined upcoming milestones, stating that Hansen expects to have a new 10 French Magellan Robotic Catheter to allow for new procedures in their vascular space. He also shared HNSN's global expansion strategy and goals for their electrophysiology business.
HNSN: 0.90 (+0.02), ISR: 1.42 (+0.02)
Boston Therapeutics' Hong Kong Affiliate Receives Department of Health Certificate to Initiate SUGARDOWN(R) Clinical Trial
Marketwired - Tue Jan 27, 6:34AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), received a signed certificate from the Department of Health to initiate a clinical trial at The Chinese University of Hong Kong (CUHK) evaluating SUGARDOWN(R) in subjects with pre-diabetes. The clinical trial is expected to start this quarter.
Boston Therapeutics' sugardown(R) Significantly Reduces Glucose, Fructose and Insulin Levels in Sugary Soft Drinks
Marketwired - Tue Jan 20, 6:01AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) released additional trial results from its Sydney University study that showed consumption of sugardown(R) tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose and insulin responses to the sugary soft drink beverage. Every subject had a reduction response. Specifically, two sugardown(R) tablets were found to reduce glucose and fructose levels by up to a total of 20 percent and insulin levels by up to 14 percent. Four sugardown(R) tablets were found to reduce total glucose and fructose levels by up to 28 percent and insulin levels by up to18 percent. These new data, which includes fructose levels, are in addition to the topline study results that were announced earlier this month that there was an average reduction in glycemic index (GI) of approximately 10 percent following soft drink consumption with two sugardown(R) tablets.
Boston Therapeutics to Present at 8th Annual OneMedForum Conference in San Francisco
Marketwired - Wed Jan 07, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will be a presenting company at the 8th Annual OneMedForum Conference to be held at the San Francisco Marriott Marquis in San Francisco, CA.
Boston Therapeutics' sugardown(R) Shown to Reduce Glucose Levels Following Consumption of Sugary Beverages
Marketwired - Tue Jan 06, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, announced that a study at Sydney University's Glycemic Index Research Service (SUGiRS) demonstrated an average reduction in glycemic index (GI) of approximately 10 percent following soft drink consumption with sugardown(R). The now-completed trial, which was co-sponsored by Boston Therapeutics and SugarDown Co Ltd (Hong Kong), was the first to evaluate sugardown(R)'s effectiveness with sugary beverages. The primary outcomes of the study were postprandial incremental glucose area under the curve (iAUC) and postprandial incremental insulin area under the curve (iAUC).
Boston Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of BTI-320 to Treat Type ll Diabetes and Weight Loss
Marketwired - Wed Dec 10, 7:21AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced that the U.S. Food and Drug Administration ("FDA" has accepted the company's Investigational New Drug Application ("IND" for BTI-320 to treat Type 2 diabetes and weight management. The primary endpoints for the multicenter trial are the mean change in Hemoglobin A1c (or HbA1c) and weight loss. The Joslin Diabetes Center in Boston will be the lead clinic in the trial, which is planned to begin in the first quarter of 2015.
Boston Therapeutics and Advance Pharmaceutical Expand Agreement to Market sugardown(R) in 12 Additional Countries in Asia
Marketwired - Fri Nov 21, 6:41AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and Advance Pharmaceutical Company Ltd., via its subsidiary Sugardown Company Ltd. of Hong Kong, have agreed to expand their marketing agreement for Boston Therapeutics' sugardown(R) to include 12 additional countries in Asia. The territory expansion comes as a result of the continued regulatory filings and marketing clearance authorizations that are being granted as Advance continues its market registration expansion.
Boston Therapeutics Initiates Clinical Study at Sydney University to Evaluate sugardown(R) With Sugary Beverage Consumption
Marketwired - Wed Nov 19, 2:43PM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company", a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and SugarDown Co Ltd (Hong Kong), are jointly sponsoring a study, which was initiated this week at Sydney University's Glycemic Index Research Service (SUGiRS), to determine postprandial glucose and insulin response to soft drink consumption with sugardown(R). This is the first study to evaluate sugardown(R)'s effectiveness with sugary beverages.
Boston Therapeutics EPS of -$0.03
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:20PM CST
Boston Therapeutics Reports Third Quarter Results and Provides Corporate Update
Marketwired - Fri Nov 07, 10:56AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate chemistry, today reported its financial results for the third quarter and nine months ended September 30, 2014 and provided a corporate update.
Boston Therapeutics Announces the North America Branding of sugardown(R): A New Natural Product That Helps Maintain Healthy Blood Sugar Levels
Marketwired - Mon Nov 03, 7:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company", a developer of complex carbohydrate therapeutics to manage post meal blood glucose levels, announced that Benchworks SD, LLC launched the branding of sugardown(R) in North America. sugardown(R) is a new natural dietary supplement product that helps people maintain healthy blood sugar levels. sugardown(R) is the first chewable tablet of its kind. It was designed for people who are committed to a balanced diet and exercise to help keep their blood sugar levels healthy.
Boston Therapeutics' Hong Kong Affiliate Advance Pharmaceutical's BTI-320 Clinical Trial Reaches Mid-Point by Enrolling 30 Patients at the Chinese University of Hong Kong
Marketwired - Wed Jul 08, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), is conducting a clinical trial at The Chinese University of Hong Kong (CUHK) to evaluate BTI-320 in subjects who are pre-diabetic. The clinical trial has enrolled 30 of the planned 60 patients. Also, the interim analysis in the proof of concept trial is due to be reported shortly.
Boston Therapeutics Presents Findings of BTI-320, a Novel, Non-Systemic, Non-Hypoglycemic Drug Candidate as Therapy to Manage Blood Glucose at 75th Annual Meeting of the American Diabetes Association
Marketwired - Mon Jun 08, 5:19AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will present data on BTI-320, its novel, non-systemic, non-hypoglycemic drug candidate to manage blood glucose, as a poster presentation at the 75th Annual Meeting of the American Diabetes Association being held in Boston, June 5th to the 9th. EC clears Boehringer Ingelheim's Synjardy
Seeking Alpha - at Seeking Alpha - Thu May 28, 9:22AM CDT
ABT: 49.93 (+0.74), TNDM: 11.47 (+0.28), VTAE: 10.26 (-0.25), LLY: 88.29 (+0.81), ALR: 52.77 (+0.40), MNKD: 5.38 (+0.25), HPTX: 45.99 (+0.02), JNJ: 99.53 (+1.13), NVO: 57.68 (+2.91), MRK: 57.95 (+0.57), SNY: 51.49 (+2.71), VKTX: 6.95 (-0.10)
Boston Therapeutics & University at Buffalo's Translational Pharmacology Research Core Initiates BTI-320 Clinical Trials Alliance in Buffalo, NY and NYC's Chinatown
Marketwired - Thu May 28, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE) signed a Letter of Intent with Dr. Gene D. Morse, Director of the Translational Pharmacology Research Core in the University at Buffalo's Center of Excellence for Bioinformatics and Life Sciences (CBLS) to potentially collaborate on an enrollment program for a preventative clinical trials initiative at several locations in Buffalo, NY and New York City's Chinatown. The purpose of this collaboration initiative is to evaluate the effects of BTI-320 on an individual's HbA1c levels, in particular, who are diabetic and pre-diabetic. HbA1c test provides an overall measurement of blood sugar levels over two to three months.
Boston Therapeutics, Inc. Reports First Quarter Results and Provides Corporate Update
Marketwired - Wed May 20, 3:55PM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate chemistry, today reported its financial results for the first quarter and three months ended March 31, 2015 and provided a corporate update.
Boston Therapeutics Announces Fourth Quarter and Fiscal Year 2014 Financial Results and Provides Corporate Update
Marketwired - Fri Mar 27, 12:15PM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate chemistry, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2014 and provided a corporate update.
Boston Therapeutics' Affiliate Advanced Pharmaceutical Initiates SUGARDOWN(R) Clinical Trial in Hong Kong
Marketwired - Wed Mar 25, 5:37AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), affiliate in Hong Kong, Advance Pharmaceutical Company, Ltd. (APC), initiated enrollment of the first subjects in a clinical trial at The Chinese University of Hong Kong to evaluate the effects of SUGARDOWN(R) who are pre-diabetic. (Trial posted on ClinicalTrials.gov)
Boston Therapeutics and Advance Pharmaceutical Expand sugardown(R) Licensing Agreement to Japan; Increases Number of Asian Countries to 16
Marketwired - Tue Mar 17, 6:00AM CDT
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of complex carbohydrates to treat diabetes and inflammatory diseases, and Advance Pharmaceutical Company Ltd. (APC), via its subsidiary Sugardown Company Ltd.(SDCL) of Hong Kong, have agreed to expand their licensing and marketing agreement for Boston Therapeutics' sugardown(R) to include Japan. The territory expansion comes as a result of the continued regulatory filings and marketing clearance authorizations that are being granted as APC continues its market registration expansion.
WSA Medical Spotlight
Marketwired - Tue Feb 17, 1:00PM CST
Hansen Medical, Inc.'s (NASDAQ: HNSN) CEO Cary Vance discussed the company's robotic systems and catheters as well as their recent IVC filter retrieval breakthrough. Mr. Vance stated he believes Hansen's technology addresses many key trends and issues hospitals are facing today including revenue-generation and cost containment. He talked about some of the benefits the IVC filter provides patients such as much safer and more effective procedures. Mr. Vance outlined upcoming milestones, stating that Hansen expects to have a new 10 French Magellan Robotic Catheter to allow for new procedures in their vascular space. He also shared HNSN's global expansion strategy and goals for their electrophysiology business.
HNSN: 0.90 (+0.02), ISR: 1.42 (+0.02)
Boston Therapeutics' Hong Kong Affiliate Receives Department of Health Certificate to Initiate SUGARDOWN(R) Clinical Trial
Marketwired - Tue Jan 27, 6:34AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) today announced that its Hong Kong affiliate, Advance Pharmaceutical Company, Ltd. (APC), received a signed certificate from the Department of Health to initiate a clinical trial at The Chinese University of Hong Kong (CUHK) evaluating SUGARDOWN(R) in subjects with pre-diabetes. The clinical trial is expected to start this quarter.
Boston Therapeutics' sugardown(R) Significantly Reduces Glucose, Fructose and Insulin Levels in Sugary Soft Drinks
Marketwired - Tue Jan 20, 6:01AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) released additional trial results from its Sydney University study that showed consumption of sugardown(R) tablets prior to sugary beverages was found to significantly reduce the postprandial glucose, fructose and insulin responses to the sugary soft drink beverage. Every subject had a reduction response. Specifically, two sugardown(R) tablets were found to reduce glucose and fructose levels by up to a total of 20 percent and insulin levels by up to 14 percent. Four sugardown(R) tablets were found to reduce total glucose and fructose levels by up to 28 percent and insulin levels by up to18 percent. These new data, which includes fructose levels, are in addition to the topline study results that were announced earlier this month that there was an average reduction in glycemic index (GI) of approximately 10 percent following soft drink consumption with two sugardown(R) tablets.
Boston Therapeutics to Present at 8th Annual OneMedForum Conference in San Francisco
Marketwired - Wed Jan 07, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, will be a presenting company at the 8th Annual OneMedForum Conference to be held at the San Francisco Marriott Marquis in San Francisco, CA.
Boston Therapeutics' sugardown(R) Shown to Reduce Glucose Levels Following Consumption of Sugary Beverages
Marketwired - Tue Jan 06, 6:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, announced that a study at Sydney University's Glycemic Index Research Service (SUGiRS) demonstrated an average reduction in glycemic index (GI) of approximately 10 percent following soft drink consumption with sugardown(R). The now-completed trial, which was co-sponsored by Boston Therapeutics and SugarDown Co Ltd (Hong Kong), was the first to evaluate sugardown(R)'s effectiveness with sugary beverages. The primary outcomes of the study were postprandial incremental glucose area under the curve (iAUC) and postprandial incremental insulin area under the curve (iAUC).
Boston Therapeutics Announces FDA Acceptance of IND to Initiate a Clinical Trial of BTI-320 to Treat Type ll Diabetes and Weight Loss
Marketwired - Wed Dec 10, 7:21AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, today announced that the U.S. Food and Drug Administration ("FDA"
has accepted the company's Investigational New Drug Application ("IND" for BTI-320 to treat Type 2 diabetes and weight management. The primary endpoints for the multicenter trial are the mean change in Hemoglobin A1c (or HbA1c) and weight loss. The Joslin Diabetes Center in Boston will be the lead clinic in the trial, which is planned to begin in the first quarter of 2015. Boston Therapeutics and Advance Pharmaceutical Expand Agreement to Market sugardown(R) in 12 Additional Countries in Asia
Marketwired - Fri Nov 21, 6:41AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and Advance Pharmaceutical Company Ltd., via its subsidiary Sugardown Company Ltd. of Hong Kong, have agreed to expand their marketing agreement for Boston Therapeutics' sugardown(R) to include 12 additional countries in Asia. The territory expansion comes as a result of the continued regulatory filings and marketing clearance authorizations that are being granted as Advance continues its market registration expansion.
Boston Therapeutics Initiates Clinical Study at Sydney University to Evaluate sugardown(R) With Sugary Beverage Consumption
Marketwired - Wed Nov 19, 2:43PM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases, and SugarDown Co Ltd (Hong Kong), are jointly sponsoring a study, which was initiated this week at Sydney University's Glycemic Index Research Service (SUGiRS), to determine postprandial glucose and insulin response to soft drink consumption with sugardown(R). This is the first study to evaluate sugardown(R)'s effectiveness with sugary beverages. Boston Therapeutics EPS of -$0.03
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 3:20PM CST
Boston Therapeutics Reports Third Quarter Results and Provides Corporate Update
Marketwired - Fri Nov 07, 10:56AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE), a leading developer of compounds that enable people to manage their blood glucose using complex carbohydrate chemistry, today reported its financial results for the third quarter and nine months ended September 30, 2014 and provided a corporate update.
Boston Therapeutics Announces the North America Branding of sugardown(R): A New Natural Product That Helps Maintain Healthy Blood Sugar Levels
Marketwired - Mon Nov 03, 7:00AM CST
Boston Therapeutics, Inc. (OTCQB: BTHE) ("Boston Therapeutics" or "the Company"
, a developer of complex carbohydrate therapeutics to manage post meal blood glucose levels, announced that Benchworks SD, LLC launched the branding of sugardown(R) in North America. sugardown(R) is a new natural dietary supplement product that helps people maintain healthy blood sugar levels. sugardown(R) is the first chewable tablet of its kind. It was designed for people who are committed to a balanced diet and exercise to help keep their blood sugar levels healthy. 
